Stockreport
Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update [Yahoo! Finance]
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
Earnings declined 1% year over year due to higher operating costs and interest expenses. Total revenues of $7.45 billion beat the Zacks Consensus Estimate of $7.38 billion. Total revenues rose 22% year over year, which was slightly better than management's expectation of growing roughly 20% in the quarter. Total product revenues increased 22% from the year-ago quarter to $7.11 billion. Higher volumes were partially offset by lower selling prices of several drugs. Volumes rose 25% in the quarter. Performance of Key Drugs General Medicine Prolia revenues came in at $999 million, up 8% from the year-ago quarter, driven by volume growth. Prolia sales beat the Zacks Consensus Estimate of $997 million but slightly missed our model estimate of $1.0 billion. Evenity recorded sales of $342 million in the quarter, up 35% year over year, driven by solid volume growth in and outside the United States. Evenity sales beat the Zacks Consensus Estimate of $334.0 million as well as our mod
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | AMGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
AMGN alerts
AMGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
NEWS
NEWS
- FDA Roundup: May 17, 2024 [Yahoo! Finance][Yahoo! Finance]
- Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC [Yahoo! Finance][Yahoo! Finance]
- U.S. FDA approves Amgen drug for small cell lung cancer [Globe and Mail, The (Toronto, Canada)][Globe and Mail, The]
- FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER[PR Newswire]
- FDA Approves Amgen Drug for Persistently Deadly Form of Lung Cancer [The New York Times][The New York Times]
- More
AMGN
SEC Filings
SEC Filings
- 5/10/24 - Form DEFA14A
- 5/9/24 - Form 4
- 5/9/24 - Form 4
- AMGN's page on the SEC website
- More